Skip to content
Simufilam
Simufilam is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03143——8
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSIMUFILAM
INNsimufilam
Description
Simufilam is an Investigational New Drug for the treatment of Alzheimer's disease in phase III clinical trials expected to finish in 2023 or 2024. It is being developed by the American pharmaceutical firm Cassava Sciences.
Classification
Small molecule
Drug classfilamin A binders
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1
Identifiers
PDB—
CAS-ID1224591-33-6
RxCUI—
ChEMBL IDCHEMBL4650230
ChEBI ID—
PubChem CID46195331
DrugBank—
UNII ID6NV440YIO0 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 18 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details